Unknown

Dataset Information

0

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.


ABSTRACT:

Background

This trial evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple-negative breast cancer (mTNBC).

Methods

Eligibility criteria were mTNBC, RECIST 1.1 measurable disease, no prior use of platinum for metastatic disease (Arms A and B), and no prior exposure to immune checkpoint inhibitor (Arm C). Primary endpoints were safety and RP2D. Secondary endpoints were progression-free survival (PFS), response rate, and overall survival.

Results

RP2D for Arm A (n = 10) was ipatasertib 300 mg daily, carboplatin AUC2, and paclitaxel 80 mg m-2 days 1, 8, and 15 every 28 days. RP2D for Arm B (n = 12) was ipatasertib 400 mg daily and carboplatin AUC2 days 1, 8, and 15 every 28 days. RP2D for Arm C (n = 6) was likely ipatasertib 300 mg 21 days on 7 days off, capecitabine 750 mg m-2, twice a day, 7 days on 7 days off, and atezolizumab 840 mg days 1 and 15 every 28 days. The most common (≥10%) grade 3-4 AEs at RP2D for Arm A (N = 7 at RP2D) were neutropenia (29%), diarrhea (14%), oral mucositis (14%), and neuropathy (14%); Arm B had diarrhea (17%) and lymphopenia (25%); and Arm C had anemia, fatigue, cognitive disturbance, and maculopapular rash (17% each). Overall responses at RP2D were 29% Arm A, 25% Arm B, and 33% Arm C. PFS was 4.8, 3.9, and 8.2 months for patients on Arms A, B, and C, respectively.

Conclusions

Continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated. Further study is warranted in understanding the role of AKT inhibition in treatment of TNBCs.

Trial registration

NCT03853707.

SUBMITTER: Yuan Y 

PROVIDER: S-EPMC10322142 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.

Yuan Yuan Y   Yost Susan E SE   Cui Yujie Y   Ruel Christopher C   Murga Mireya M   Tang Aileen A   Martinez Norma N   Schmolze Daniel D   Waisman James J   Patel Niki N   Vora Lalit L   Tumyan Lusine L   Bozoghlanian Mari M   Stewart Daphne D   Frankel Paul H PH  

The oncologist 20230701 7


<h4>Background</h4>This trial evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple-negative breast cancer (mTNBC).<h4>Methods</h4>Eligibility criteria were mTNBC, RECIST 1.1 measurable disease, no prior use of platinum for metastatic disease (Arms A and B), and no prior exposure to immune checkpoint inhibitor (Arm C). Primary endpoints were safety and RP2D. Secondary endpoints wer  ...[more]

Similar Datasets

| S-EPMC5626630 | biostudies-literature
| S-EPMC10284878 | biostudies-literature
| S-EPMC11443247 | biostudies-literature
| S-EPMC10870115 | biostudies-literature
| S-EPMC6439843 | biostudies-literature
| S-EPMC6096741 | biostudies-literature
| S-EPMC9803651 | biostudies-literature
| S-EPMC3265117 | biostudies-literature
| S-EPMC4783742 | biostudies-literature
| S-EPMC9800277 | biostudies-literature